Dow Down0.78% Nasdaq Down1.13%

Vertex Pharmaceuticals Incorporated (VRTX)

82.16 Down 0.84(1.01%) May 3, 4:00PM EDT
|After Hours : 82.16 0.00 (0.00%) May 3, 5:02PM EDT
ProfileGet Profile for:
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
United States - Map
Phone: 617-341-6100

Index Membership:N/A
Full Time Employees:1,950

Business Summary 

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their CFTR gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 6 years of age and older who have the G551D mutation in their CFTR gene. The company also develops VX-661, a corrector compound that is in a Phase III development stage in combination with ivacaftor in multiple CF patients; VX-371, an investigational epithelial sodium channel, which is in a Phase II development stage; and VX-152 and VX-440 that are CFTR corrector compounds in Phase I clinical trial. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers in international markets. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; BioAxone Biosciences, Inc.; and Janssen Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Vertex Pharmaceuticals Incorporated

Corporate Governance 
Vertex Pharmaceuticals Incorporated’s ISS Governance QuickScore as of May 1, 2016 is 10. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 10; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Jeffrey M. Leiden M.D., Ph.D., 60
Chairman, Chief Exec. Officer and Pres
Mr. Ian F. Smith CPA, ACA, 50
Chief Financial Officer and Exec. VP
Dr. David Altshuler M.D., Ph.D., 51
Chief Scientific Officer and Exec. VP of Global Research
Mr. Stuart A. Arbuckle B.Sc., 50
Chief Commercial Officer and Exec. VP
Dr. Jeffrey A. Chodakewitz M.D., 60
Chief Medical Officer and Exec. VP of Global Medicines Devel. & Medical Affairs
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders